{"id":"metronidazole-and-rifampin","safety":{"commonSideEffects":[{"rate":null,"effect":"Metallic taste"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Drug interactions (rifampin enzyme induction)"}]},"_chembl":{"chemblId":"CHEMBL137","moleculeType":"Small molecule","molecularWeight":"171.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metronidazole is a nitroimidazole that generates reactive oxygen species and damages bacterial DNA, while rifampin inhibits bacterial RNA polymerase II, blocking transcription. The combination provides synergistic activity against anaerobic bacteria and certain aerobic pathogens, potentially overcoming resistance mechanisms and improving clinical outcomes in polymicrobial or difficult-to-treat infections.","oneSentence":"Metronidazole and rifampin are a combination of an antibiotic that disrupts bacterial DNA and an antibiotic that inhibits bacterial RNA polymerase, used together to treat infections resistant to single-agent therapy.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:21:09.648Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Polymicrobial infections or resistant anaerobic infections (Phase 3 investigational)"}]},"trialDetails":[{"nctId":"NCT07429760","phase":"NA","title":"Mechanical Bowel Preparation With or Without Oral Antibiotics in Left Sided Colorectal Cancer Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"Shaukat Khanum Memorial Cancer Hospital & Research Centre","startDate":"2025-08-01","conditions":"Colorectal Cancer","enrollment":60},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":"Mild Cognitive Impairment, Dementia, Mild","enrollment":73},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT05821478","phase":"PHASE3","title":"Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients","status":"RECRUITING","sponsor":"Institut Pasteur","startDate":"2025-05-22","conditions":"Hidradenitis Suppurativa","enrollment":92},{"nctId":"NCT04525235","phase":"PHASE1","title":"Phenotyping of High Dose Rifampicin","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-01-07","conditions":"Tuberculosis","enrollment":25},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT00182429","phase":"PHASE3","title":"Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment","status":"COMPLETED","sponsor":"McMaster University","startDate":"2004-02","conditions":"Clostridium Enterocolitis, Antibiotic-Associated Diarrhea, Pseudomembranous Colitis","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Metronidazole and Rifampin","genericName":"Metronidazole and Rifampin","companyName":"McMaster University","companyId":"mcmaster-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metronidazole and rifampin are a combination of an antibiotic that disrupts bacterial DNA and an antibiotic that inhibits bacterial RNA polymerase, used together to treat infections resistant to single-agent therapy. Used for Polymicrobial infections or resistant anaerobic infections (Phase 3 investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}